Technology Assessment

We are de-risking biomedical innovations, turning biomedical knowledge into social and economic value.

Technology Assessment

Mercury Pharmaceuticals

The process of bringing your healthcare innovation to the market is lengthy and complicated. Besides the clinical or humanistic value that your product generates, for example by decreasing complication rate, prolonging survival, improving patient flow etc., the economic value needs to be demonstrated to healthcare payers.

Using Health Technology Assessment, the value of a novel medical intervention is quantified by simultaneous analysis of effects on patient outcomes and total costs of care associated with the innovation in comparison to the standard of care. An objective measure of the medical innovation’s value is generally required for (national) reimbursement applications.

Mercury Pharmaceuticals offers tailor-made Health Technology Assessment expertise through:

    Mercury Pharmaceuticals
  • Development-focused health technology assessment: even in the early stages of development when complete clinical data is not (yet) available, an estimation of expected value can be made using experts-inputs and small scale studies
  • Extensive literature review of the relevant standard of care pathway and associated costs, establishing the baseline to which your innovation will be compared by payers
  • Developing, analyzing and validating health economic models, including translating and updating  existing models with new (country-specific) data
  • Development of value dossiers for all relevant stakeholders
  • Preparation of reimbursement files

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

STAY INFORMED!

PMOS rethink reframes a common hormone disorder as a whole-body disease

18

Jun 2026

PMOS rethink reframes a common hormone disorder as a whole-body disease

A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.

READ MORE
New biological age tools could reveal health risks before symptoms appear

18

Jun 2026

New biological age tools could reveal health risks before symptoms appear

A JCI review traces biological age measurement from functional tests and blood biomarkers to epigenetic, proteomic, imaging, wearable, and AI-based clocks. It finds that these tools can improve risk prediction beyond chronological age, but standardization, interpretability, and prospective validation are needed before routine clinical use.

READ MORE
Aircraft emissions could double air pollution deaths by 2040

18

Jun 2026

Aircraft emissions could double air pollution deaths by 2040

Scenario-based modeling projects that aviation-related air pollution could drive a major rise in premature deaths by 2040, mainly through PM2.5 and ozone exposure. The study estimates that aircraft emissions caused 33,900 PM2.5-related deaths and 24,600 ozone-related deaths in 2019, with baseline 2040 deaths projected to more than double.

READ MORE

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.